Protein engineering of the tissue inhibitor of metalloproteinase 1 (TIMP-1) inhibitory domain. In search of selective matrix metalloproteinase inhibitors.
about
Targeting matrix metalloproteinases in heart disease: lessons from endogenous inhibitorsMatrix Metalloproteinase-10 (MMP-10) Interaction with Tissue Inhibitors of Metalloproteinases TIMP-1 and TIMP-2: BINDING STUDIES AND CRYSTAL STRUCTUREAffinity- and specificity-enhancing mutations are frequent in multispecific interactions between TIMP2 and MMPsUrokinase directly activates matrix metalloproteinases-9: a potential role in glioblastoma invasionDisease-modifying osteoarthritis drugs: in vitro and in vivo data on the development of DMOADs under investigation.Engineered sarafotoxins as tissue inhibitor of metalloproteinases-like matrix metalloproteinase inhibitors.Inactivation of N-TIMP-1 by N-terminal acetylation when expressed in bacteria.Progress in matrix metalloproteinase research.Thoracic aortic dissection: are matrix metalloproteinases involved?Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer.Phage display of tissue inhibitor of metalloproteinases-2 (TIMP-2): identification of selective inhibitors of collagenase-1 (metalloproteinase 1 (MMP-1))Reactive-site mutants of N-TIMP-3 that selectively inhibit ADAMTS-4 and ADAMTS-5: biological and structural implicationsEntropy increases from different sources support the high-affinity binding of the N-terminal inhibitory domains of tissue inhibitors of metalloproteinases to the catalytic domains of matrix metalloproteinases-1 and -3.Dynamic interdomain interactions contribute to the inhibition of matrix metalloproteinases by tissue inhibitors of metalloproteinases.The orthologous Tbx transcription factors Omb and TBX2 induce epithelial cell migration and extrusion in vivo without involvement of matrix metalloproteinasesMatrix metalloproteinases as breast cancer drivers and therapeutic targets.Constraining specificity in the N-domain of tissue inhibitor of metalloproteinases-1; gelatinase-selective inhibitors.Peptide-based selective inhibitors of matrix metalloproteinase-mediated activitiesThermodynamic Basis of Selectivity in the Interactions of Tissue Inhibitors of Metalloproteinases N-domains with Matrix Metalloproteinases-1, -3, and -14.Predicting affinity- and specificity-enhancing mutations at protein-protein interfaces.Exogenously added GPI-anchored tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) displays enhanced and novel biological activities.Therapeutic Potential of Matrix Metalloproteinase Inhibition in Breast Cancer.Association of TIMP-1 and TIMP-2 gene polymorphisms with progression of liver fibrosis in patients with type C chronic liver disease.Unveiling the surface epitopes that render tissue inhibitor of metalloproteinase-1 inactive against membrane type 1-matrix metalloproteinase.Development of High Affinity and High Specificity Inhibitors of Matrix Metalloproteinase 14 through Computational Design and Directed Evolution.Reactive site mutations in tissue inhibitor of metalloproteinase-3 disrupt inhibition of matrix metalloproteinases but not tumor necrosis factor-alpha-converting enzyme.Converting a broad matrix metalloproteinase family inhibitor into a specific inhibitor of MMP-9 and MMP-14.Crystal structure of the catalytic domain of matrix metalloproteinase-1 in complex with the inhibitory domain of tissue inhibitor of metalloproteinase-1.MicroRNA-645 targets urokinase plasminogen activator and decreases the invasive growth of MDA-MB-231 triple-negative breast cancer cells
P2860
Q26830555-86EF4BA8-DA6B-4AF4-A226-4A0CA147388DQ27678085-69092EEF-B31A-4ECB-B17B-5087368C3FBCQ28542042-11A4F3F6-D9DF-4E46-9329-CCCF18592125Q30439641-BC86AA53-73B2-4977-BDB6-5A2B90B8F24FQ30588700-B6D79972-1390-4152-B1EF-B62567B93718Q33290604-31A07A5E-B7C7-42D4-A67B-D39BC759B8E5Q33581798-5FFA7587-95EB-4F74-AA17-85147B8C0D2AQ33608536-53C206D4-82D5-4156-B219-B311F1E70545Q33745506-FAAC7E58-081A-451C-90A1-7C626B23E5ECQ33915005-3563FCB0-E457-4E5D-8BD2-91ED920F57B5Q33946167-99A18C29-6D9D-4508-B6ED-F2030F5EE0ACQ34412131-4E78C1CF-4784-47AB-92CF-8F7626F79A3FQ34947735-06EA366A-2447-46C6-B961-73410B2529ABQ35063432-DEE3FBB9-2DD9-403A-8EED-912580A51A97Q35067915-131054D7-40E8-4922-8B06-A29A75CBA23FQ35892721-82941570-2EF2-4AB5-9066-7D2CA2F789A9Q36393553-9E1250D7-28FA-4CF4-8958-748683315338Q36919032-1154B328-98F1-42E9-BF9A-872271710532Q36987704-E6E66D86-4B23-4315-AA33-77073E8B74A0Q38141059-250E8B15-6828-43EA-B6AF-43E6481DE224Q40524187-63BB47E9-8018-418A-9FED-5D869CF72DBEQ42720277-D5EB0D61-1611-43CB-8817-3156CE9C773EQ43742587-790AD75D-9BB0-4D7C-B713-D88564C54737Q44517538-F22C8AC8-2831-4C8D-B379-359D19B09F7EQ51044896-5D5A8CBC-A73B-49F2-B1D1-3FD48DE9978FQ51380060-C3E132FC-7156-4BCA-9B37-5DE76766144EQ52688539-D155C83B-5006-48DE-9AE9-17EE484456A7Q54453435-86AC5BF1-D99C-4711-9FBD-38853C65E39DQ59135086-BF97C962-CA67-4EC2-91FF-61794F3069F6
P2860
Protein engineering of the tissue inhibitor of metalloproteinase 1 (TIMP-1) inhibitory domain. In search of selective matrix metalloproteinase inhibitors.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Protein engineering of the tis ...... metalloproteinase inhibitors.
@en
Protein engineering of the tissue inhibitor of metalloproteinase 1
@nl
type
label
Protein engineering of the tis ...... metalloproteinase inhibitors.
@en
Protein engineering of the tissue inhibitor of metalloproteinase 1
@nl
prefLabel
Protein engineering of the tis ...... metalloproteinase inhibitors.
@en
Protein engineering of the tissue inhibitor of metalloproteinase 1
@nl
P2093
P2860
P356
P1476
Protein engineering of the tis ...... metalloproteinase inhibitors.
@en
P2093
Hideaki Nagase
Keith Brew
Linda Chung
P2860
P304
P356
10.1074/JBC.M211793200
P407
P577
2003-01-06T00:00:00Z